CD38 Antibody (2Q1628): sc-70654
- CD38 Antibody (2Q1628) is a rat monoclonal IgG2a, cited in 1 publications, provided at 200 µg/ml
- raised against partially purified CD38 from mouse bone marrow pre-B cells
- recommended for detection of CD38 of mouse origin by IF and FCM
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CD38 Antibody (2Q1628). This work is in progress.
QUICK LINKS
SEE ALSO...
CD38 Antibody (2Q1628) is a rat monoclonal IgG2a antibody that detects CD38 in mouse samples through immunofluorescence (IF) and flow cytometry (FCM) applications. CD38 is a type II integral membrane glycoprotein predominantly expressed on early B and T cell lineages, activated B and T cells, and various other immune cells, including thymocytes, pre-B cells, germinal center B cells, and Ig-secreting plasma cells. CD38′s presence is notably absent in most mature resting peripheral lymphocytes, highlighting CD38′s role in immune activation. CD38 functions as a NAD glycohydrolase, playing a crucial role in T lymphocyte activation, proliferation, and differentiation, while also mediating apoptosis in myeloid and lymphoid progenitor cells. CD38 acts as both a signaling receptor and an enzyme that generates calcium-mobilizing metabolites, such as cyclic adenosine diphosphate ribose (cADPR), which are vital for intracellular signaling pathways. CD38 is essential for the survival of invariant natural killer T (iNKT) cells, which are key players in maintaining immunological tolerance, thereby underscoring CD38′s significance in both adaptive and innate immune responses. Anti-CD38 antibody (2Q1628) is an invaluable tool for researchers studying immune cell dynamics and signaling pathways in mouse models.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD38 Antibody (2Q1628) References:
- CD38 Monoclonal Antibody Therapies for Multiple Myeloma. | Wong, SW. and Comenzo, RL. 2015. Clin Lymphoma Myeloma Leuk. 15: 635-45. PMID: 26443328
- CD38 as an immunotherapeutic target in multiple myeloma. | Bonello, F., et al. 2018. Expert Opin Biol Ther. 18: 1209-1221. PMID: 30394809
- Role of CD38/cADPR signaling in obstructive pulmonary diseases. | Guedes, AG., et al. 2020. Curr Opin Pharmacol. 51: 29-33. PMID: 32480246
- CD38 and Regulation of the Immune Response Cells in Cancer. | Dwivedi, S., et al. 2021. J Oncol. 2021: 6630295. PMID: 33727923
- CD38-Directed Therapies for Management of Multiple Myeloma. | Hashmi, H., et al. 2021. Immunotargets Ther. 10: 201-211. PMID: 34235096
- Implications of the NADase CD38 in COVID pathophysiology. | Zeidler, JD., et al. 2022. Physiol Rev. 102: 339-341. PMID: 34494892
- Profiling Glutathionylome in CD38-Mediated Epithelial-Mesenchymal Transition. | Ma, Y., et al. 2022. J Proteome Res. 21: 1240-1250. PMID: 35420434
- Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity. | Hiemstra, IH., et al. 2023. EBioMedicine. 93: 104663. PMID: 37379657
- CD38hiCD8+ T cells characterize ICI-mediated arthritis. | Phillips, R. 2023. Nat Rev Rheumatol. 19: 605. PMID: 37674050
- Exosomes miRNA-499a-5p targeted CD38 to alleviate anthraquinone induced cardiotoxicity: experimental research. | Ma, C., et al. 2024. Int J Surg. 110: 1992-2006. PMID: 38277348
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD38 Antibody (2Q1628) | sc-70654 | 200 µg/ml | $322.00 |